Tag Archives: Alzheimer’s

Aduhelm and Alzheimer’s Disease: A Potential Medicare Budget-Buster Puts A Blazing Light on Health Care Costs and Innovation

The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. health care costs and spending, innovation, and return-on-the-investment (as well as “for whom” do the returns accrue). In my latest post for Medecision, I explore different angles on the Aduhelm and Alzheimer’s… Read More »

McGill study identifies new role of major genetic risk factor in Alzheimer’s disease

For years, physicians have been aware that patients carrying the apolipoprotein ꜫ4 (APOE ꜫ4) gene are at a greater risk of developing Alzheimer’s disease. New research from McGill University has now found the gene plays an even greater role in dementia. In a study published today in the Journal of the American Medical Association: Neurology, Dr. Pedro… Read More »

Parkinson’s drug may help curb delusions in Alzheimer’s patients

SAN DIEGO — A drug that curbs delusions in Parkinson’s patients did the same for people with Alzheimer’s disease and other forms of dementia in a study that was stopped early because the benefit seemed clear. If regulators agree, the drug could become the first treatment specifically for dementia-related psychosis and the first new medicine… Read More »

China gives conditional OK to its first self-developed Alzheimer’s drug

BEIJING (Reuters) – China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. Oligomannate, which uses extract from marine brown algae as raw material, received a conditional… Read More »